144 related articles for article (PubMed ID: 20926592)
1. Limited utility of oral glucose tolerance test in biochemically active acromegaly.
Ribeiro-Oliveira A; Faje AT; Barkan AL
Eur J Endocrinol; 2011 Jan; 164(1):17-22. PubMed ID: 20926592
[TBL] [Abstract][Full Text] [Related]
2. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
3. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
4. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
5. Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
Dobri G; Niwattisaiwong S; Bena JF; Gupta M; Kirwan J; Kennedy L; Hamrahian AH
Endocrine; 2019 Apr; 64(1):139-146. PubMed ID: 30415402
[TBL] [Abstract][Full Text] [Related]
6. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
7. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
[TBL] [Abstract][Full Text] [Related]
8. Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.
Carosi G; Mangone A; Sala E; Del Sindaco G; Mungari R; Cremaschi A; Ferrante E; Arosio M; Mantovani G
Eur J Endocrinol; 2021 Jul; 185(2):289-297. PubMed ID: 34081617
[TBL] [Abstract][Full Text] [Related]
9. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly.
Grottoli S; Razzore P; Gaia D; Gasperi M; Giusti M; Colao A; Ciccarelli E; Gasco V; Martino E; Ghigo E; Camanni F
J Endocrinol Invest; 2003 Feb; 26(2):123-7. PubMed ID: 12739738
[TBL] [Abstract][Full Text] [Related]
10. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Bruce JN
Pituitary; 2003; 6(4):175-80. PubMed ID: 15237928
[TBL] [Abstract][Full Text] [Related]
11. DISCORDANCE BETWEEN GH AND IGF-1 LEVELS IN TURKISH ACROMEGALIC PATIENTS.
Cerit ET; Ağbaht K; Demir Ö; Şahin M; Gedik VT; Özcan C; Çorapçıoğlu D
Endocr Pract; 2016 Dec; 22(12):1422-1428. PubMed ID: 27631850
[TBL] [Abstract][Full Text] [Related]
12. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
[TBL] [Abstract][Full Text] [Related]
13. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
14. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
15. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
16. Comparison of oral glucose tolerance test (OGTT) 100 g with OGTT 75 g for evaluation of acromegalic patients and the impact of gender on test reproducibility.
Arafat AM; Müller L; Möhlig M; Mayr B; Kremenevskaya N; Pfeiffer AF; Buchfelder M; Schöfl C
Clin Endocrinol (Oxf); 2011 Nov; 75(5):685-91. PubMed ID: 21575028
[TBL] [Abstract][Full Text] [Related]
17. Gender and age in the biochemical assessment of cure of acromegaly.
Freda PU; Landman RE; Sundeen RE; Post KD
Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
[TBL] [Abstract][Full Text] [Related]
18. Reliability of the oral glucose tolerance test in the early postoperative assessment of acromegaly remission.
Kristof RA; Neuloh G; Redel L; Klingmüller D; Schramm J
J Neurosurg; 2002 Dec; 97(6):1282-6. PubMed ID: 12507124
[TBL] [Abstract][Full Text] [Related]
19. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
20. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]